Breaking News, Collaborations & Alliances

AGC Biologics Produces New T1D Treatment from Provention Bio

TZIELD delays the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older.

Author Image

By: Charlie Sternberg

Associate Editor

AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new commercial manufacturing project at its Seattle protein biologics manufacturing site.   The CDMO is producing TZIELD (teplizumab-mzwv), a new T1D treatment from Provention Bio Inc., a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases.   Prove...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters